Kyverna Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Bain Capital Life Sciences Opportunities III, LP reports a 4.75% ownership stake in Kyverna Therapeutics, Inc. as of June 30, 2026.
NASDAQ
Westlake BioPartners entities and Dr. Beth C. Seidenberg filed an amended Schedule 13G for Kyverna Therapeutics, Inc., reporting a combined 7.8% beneficial ownership.
NASDAQ
GordonMD Global Investments and related entities report a 7.0% beneficial ownership stake in Kyverna Therapeutics, Inc. common stock.